Aarti Pharmalabs Limited - Asset Resilience Ratio

Latest as of March 2025: 1.69%

Aarti Pharmalabs Limited (AARTIPHARM) has an Asset Resilience Ratio of 1.69% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Rs491.23 Million

≈ $5.31 Million USD Cash + Short-term Investments

Total Assets

Rs29.06 Billion

≈ $314.32 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2023–2025)

This chart shows how Aarti Pharmalabs Limited's Asset Resilience Ratio has changed over time. See AARTIPHARM financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Aarti Pharmalabs Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AARTIPHARM stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs0.00	0%
Short-term Investments	Rs491.23 Million	1.69%
Total Liquid Assets	Rs491.23 Million	1.69%

Asset Resilience Insights

Limited Liquidity: Aarti Pharmalabs Limited maintains only 1.69% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Aarti Pharmalabs Limited Industry Peers by Asset Resilience Ratio

Compare Aarti Pharmalabs Limited's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Drug Manufacturers - Specialty & Generic	0.20%
Shan Dong Dong-E E-Jiao Co Ltd SHE:000423	Drug Manufacturers - Specialty & Generic	20.44%
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	Drug Manufacturers - Specialty & Generic	48.48%
Tasly Pharmaceutical Group Co Ltd SHG:600535	Drug Manufacturers - Specialty & Generic	11.69%
Chengdu Kanghong Pharmaceuticals Group Co Ltd SHE:002773	Drug Manufacturers - Specialty & Generic	4.31%
Tibet Rhodiola Pharmaceutical Holding Co SHG:600211	Drug Manufacturers - Specialty & Generic	15.57%
Beijing New Oriental Star Petrochemical Engineering Co Ltd SHE:002755	Drug Manufacturers - Specialty & Generic	24.59%
Changzhou Qianhong Biopharma Co Ltd SHE:002550	Drug Manufacturers - Specialty & Generic	18.70%

Annual Asset Resilience Ratio for Aarti Pharmalabs Limited (2023–2025)

The table below shows the annual Asset Resilience Ratio data for Aarti Pharmalabs Limited.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	1.69%	Rs491.23 Million ≈ $5.31 Million	Rs29.06 Billion ≈ $314.32 Million	-1.04pp
2024-03-31	2.73%	Rs703.98 Million ≈ $7.61 Million	Rs25.82 Billion ≈ $279.24 Million	+0.45pp
2023-03-31	2.27%	Rs509.90 Million ≈ $5.51 Million	Rs22.44 Billion ≈ $242.68 Million	--

pp = percentage points

About Aarti Pharmalabs Limited

NSE:AARTIPHARM India Drug Manufacturers - Specialty & Generic

Market Cap

$654.02 Million

Rs60.48 Billion INR

Market Cap Rank

#10716 Global

#539 in India

Share Price

Rs667.15

Change (1 day)

-1.06%

52-Week Range

Rs591.95 - Rs939.50

All Time High

Rs964.90